A glance at what’s happening in the world of technology.
1. Tiny implant for rare, sight-robbing disease shows efficacy
The first Food and Drug Administration-approved treatment for a rare, progressive retinal neurovascular and glial degenerative disease has been found to demonstrate efficacy in the latest round of trials.
Macular telangiectasia type 2 (MacTel) produces a macular photoreceptor atrophy and loss of central vision in patients.
The study, published in NEJM Evidence, investigated the efficacy and safety of revakinagene taroretcel (NT-501) in two phase III trials. These found that NT-501 resulted in a statistically significant reduced progression of ellipsoid zone area loss.
The researchers concluded that the implant may provide a protected environment for retinal pigment epithelial cells to survive and secrete therapeutic levels of ciliary neurotrophic factor.
Sign in to continue
Not already a member of the College?
Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
The College of Optometrists has responded to the GOC consultation on the proposed updated statement on testing of sight and proposed supervision and delegation standards.
The GOC’s findings indicate strong patient satisfaction with eye care services but identifies that registrants have concerns that commercial pressures could potentially impact their ability to deliver the best possible care to patients, as well as affecting their wellbeing.